ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,0856
0,01%
Bitcoin
69.980,97
-0,21%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AngioDynamics Inc (ANGO)

  7. AngioDynamics Inc (ANGO) News

ANGO

AngioDynamics (ANGO)

AngioDynamics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ANGO
DatumZeitQuelleÜberschriftSymbolFirma
21/05/202423h30Business WireAngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ SystemNASDAQ:ANGOAngioDynamics Inc
06/05/202422h45Business WireAngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific SessionsNASDAQ:ANGOAngioDynamics Inc
04/04/202413h31IH Market NewsUS Index Futures Rise, Oil Dips SlightlyNASDAQ:ANGOAngioDynamics Inc
04/04/202413h00Business WireAngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset DivestitureNASDAQ:ANGOAngioDynamics Inc
04/04/202412h45Business WireAngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PENASDAQ:ANGOAngioDynamics Inc
01/04/202423h26Business WireAngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.NASDAQ:ANGOAngioDynamics Inc
19/03/202421h01Business WireAngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024NASDAQ:ANGOAngioDynamics Inc
06/03/202422h01Business WireAngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services ConferenceNASDAQ:ANGOAngioDynamics Inc
05/03/202402h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANGOAngioDynamics Inc
15/02/202422h05Business WireAngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 MillionNASDAQ:ANGOAngioDynamics Inc
23/01/202422h14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANGOAngioDynamics Inc
23/01/202414h00Business WireAngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial DiseaseNASDAQ:ANGOAngioDynamics Inc
22/01/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
11/01/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
08/01/202422h47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANGOAngioDynamics Inc
05/01/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
05/01/202413h00Business WireAngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 GuidanceNASDAQ:ANGOAngioDynamics Inc
21/12/202322h01Business WireAngioDynamics to Present at the J.P. Morgan Healthcare ConferenceNASDAQ:ANGOAngioDynamics Inc
07/12/202322h01Business WireAngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024NASDAQ:ANGOAngioDynamics Inc
07/12/202314h00Business WireAngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary EmbolismNASDAQ:ANGOAngioDynamics Inc
07/11/202314h03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ANGOAngioDynamics Inc
06/10/202320h34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANGOAngioDynamics Inc
05/10/202323h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANGOAngioDynamics Inc
04/10/202313h22IH Market NewsWednesday’s Wall Street Highlights: Apple, Intel, Cal-Maine, A10 Networks, and moreNASDAQ:ANGOAngioDynamics Inc
04/10/202313h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
04/10/202313h00Business WireAngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 GuidanceNASDAQ:ANGOAngioDynamics Inc
22/09/202303h28Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
22/09/202303h23Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
22/09/202303h17Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
22/09/202303h12Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
 Showing the most relevant articles for your search:NASDAQ:ANGO

Kürzlich von Ihnen besucht

COIN
BTCUSD
Bitcoin
TG
LHA
Deutsche Lufthansa
AMEX
SPY
SPDR S&P 500
TG
MBG
MercedesBenz
USOTC
ADDYY
Adidas (QX)
TG
RHM
Rheinmetall
TG
D7G
Nel ASA
AMEX
XLF
Financial Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
TG
432
Arbor Metals
CCOM
US500
US 500
PM
XAUUSD
Gold vs US Dollar
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLV
Health Care Select Sector
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten